Peter Hecht Biography and Net Worth

Dr. Hecht served as the co-founder and chief executive officer of Ironwood Pharmaceuticals from 1998 to 2019. Under his leadership, Ironwood grew from nine Ph.D. scientists to a commercial biotechnology company that discovered, developed and is now commercializing LINZESS^® – the branded prescription market leader in its class. Additionally, during his tenure the company pioneered new areas of science, delivered a promising development portfolio with multiple innovative drug candidates and established a valuable network of global partnerships. Through a combination of private and public equity, structured debt and partnerships, Dr. Hecht and his team raised over one billion dollars to fund these efforts. He also served on the Ironwood board from 1998 to 2019, and currently serves on the board of Kallyope Inc., a privately held biotechnology company.  Prior to founding Ironwood, Dr. Hecht was a research fellow at Whitehead Institute for Biomedical Research. Dr. Hecht earned a B.S. in mathematics and an M.S. in biology from Stanford University, and a Ph.D. in molecular biology from the University of California at Berkeley.

What is Peter M. Hecht's net worth?: The estimated net worth of Peter M. Hecht is at least $51.04 thousand as of June 3rd, 2021. Dr. Hecht owns 14,626 shares of Cyclerion Therapeutics stock worth more than $51,045 as of October 9th. This net worth estimate does not reflect any other investments that Dr. Hecht may own. Learn More about Peter M. Hecht's net worth.
How do I contact Peter M. Hecht?: The corporate mailing address for Dr. Hecht and other Cyclerion Therapeutics executives is 301 BINNEY STREET, CAMBRIDGE MA, 02142. Cyclerion Therapeutics can also be reached via phone at (857) 327-8778 and via email at [email protected]. Learn More on Peter M. Hecht's contact information.
Has Peter M. Hecht been buying or selling shares of Cyclerion Therapeutics?: Peter M. Hecht has not been actively trading shares of Cyclerion Therapeutics within the last three months. Most recently, on Thursday, June 3rd, Peter M. Hecht bought 5,879 shares of Cyclerion Therapeutics stock. The stock was acquired at an average cost of $459.20 per share, with a total value of $2,699,636.80. Following the completion of the transaction, the chief executive officer now directly owns 14,626 shares of the company's stock, valued at $6,716,259.20. Learn More on Peter M. Hecht's trading history.
Who are Cyclerion Therapeutics' active insiders?: Cyclerion Therapeutics' insider roster includes Peter Hecht (CEO), and Terrance Mcguire (Director). Learn More on Cyclerion Therapeutics' active insiders.

Peter M. Hecht Insider Trading History at Cyclerion Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/3/2021	Buy	5,879	$459.20	$2,699,636.80	14,626
5/6/2021	Buy	2,157	$340.20	$733,811.40	8,746
5/4/2021	Buy	2,142	$320.60	$686,725.20	3,746

Peter M. Hecht Buying and Selling Activity at Cyclerion Therapeutics

Cyclerion Therapeutics Company Overview

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $34.92

$33.33

$35.15

50 Day Range

MA: N/A

2 Week Range

Now: $34.92

$7.19

$59.36

Volume

21,321 shs

Average Volume

290,871 shs

Market Capitalization

$23.39 million

P/E Ratio

N/A

Dividend Yield